Please login to the form below

Not currently logged in


This page shows the latest ibrutinib news and features for those working in and with pharma, biotech and healthcare.

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Settlement clears path for Biogen, Samsung’s Humira biosimilar

The company has made strenuous efforts to diversify into areas such as cancer, and has high hopes for new launches such as blood cancer therapies Imbruvica (ibrutinib) and Venclexta (venetoclax).

Latest news

More from news
Approximately 17 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Pharma deals during November 2014 Pharma deals during November 2014

    Whatever CAR-T's promise, for the time being of course the chronic lymphocytic leukaemia company to beat is Pharmacyclics with Imbruvic (ibrutinib), its oral small molecule still proving remarkably resilient ... Ibrutinib blocks signals that tell

  • Pharma deals during October 2014 Pharma deals during October 2014

    This clinical trial collaboration will look at a phase 1/2 study for Opdivo in combination with Imbruvica [ibrutinib – an oral Bruton's kinase inhibitor] as a treatment option for

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Quest Diagnostics / Royalty Pharma. Purchase of royalty rights. Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3).

  • Pharma deals during July 2013 Pharma deals during July 2013

    However, Royalty Pharma did close a deal this month with presumably a fully cooperative partner, Quest Diagnostics, which had deemed the phase III anticancer drug ibrutinib to be non-core and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...